Oxford Biomedica Transforms With New Deals, R&D Pipeline, And Manufacturing Facilities

CAR-T and TCR-T Program Deal Signed With Juno

The lentivirus gene delivery company, Oxford Biomedica, is to collaborate with Juno Therapeutics on its CAR-T and TCR-T projects, adding to the UK biotech’s transformation into a debt-free company with a growing in-house product pipeline.  

Trolley_DNA_Molecule
• Source: Shutterstock

The UK gene and cell therapy company, Oxford BioMedica PLC, has transformed its business over the past year, becoming debt-free, signing new collaborations with big pharma, and is now progressing a pipeline of preclinical product candidates using its lentivirus gene-delivery platform. Its latest revenue-earner is a $200m tie-up with Juno Therapeutics Inc..

Juno Therapeutics, a Bristol-Myers Squibb Co. subsidiary, has received a non-exclusive license to Oxford Biomedica’s LentiVector platform to use...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.